SNSS - サネシス・ファ―マス―ティカルズ （Sunesis Pharmaceuticals Inc.）

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined,…

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ), a biopharma focused on developing targeted therapies for hematologic and solid cancers, filed its annual report on Form 10-K with the SEC. The company had announced in November an agreement to merge with privately-held precision oncology company Viracta Therapeutics. In an 8-K filing Tuesday, the company said each of the five proposals related to the merger was approved by the requisite vote at the special shareholder meeting held Feb. 22, paving way for the closing of the transaction. Sunesis shares were climbing 26.46% to … Full story available on Benzinga.com

NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Sunesis Pharmaceuticals, Inc. ("SNSS" or the "Company") (SNSS)…

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesis Pharmaceuticals, Inc. (NasdaqGS: SNSS) with Viracta Therapeutics, Inc. pursuant to which Sunesis shareholders will end up owning just 14% of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger u

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares shot up 11.9% during mid-day trading on Friday . The stock traded as high as $1.55 and last traded at $1.46. 1,999,292 shares were traded during trading, an increase of 177% from the average session volume of 721,360 shares. The stock had previously closed at $1.30. A number of analysts […]

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined,…

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ), a biopharma focused on developing targeted therapies for hematologic and solid cancers, filed its annual report on Form 10-K with the SEC. The company had announced in November an agreement to merge with privately-held precision oncology company Viracta Therapeutics. In an 8-K filing Tuesday, the company said each of the five proposals related to the merger was approved by the requisite vote at the special shareholder meeting held Feb. 22, paving way for the closing of the transaction. Sunesis shares were climbing 26.46% to … Full story available on Benzinga.com

NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Sunesis Pharmaceuticals, Inc. ("SNSS" or the "Company") (SNSS)…

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesis Pharmaceuticals, Inc. (NasdaqGS: SNSS) with Viracta Therapeutics, Inc. pursuant to which Sunesis shareholders will end up owning just 14% of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger u

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares shot up 11.9% during mid-day trading on Friday . The stock traded as high as $1.55 and last traded at $1.46. 1,999,292 shares were traded during trading, an increase of 177% from the average session volume of 721,360 shares. The stock had previously closed at $1.30. A number of analysts […]

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined,…

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ), a biopharma focused on developing targeted therapies for hematologic and solid cancers, filed its annual report on Form 10-K with the SEC. The company had announced in November an agreement to merge with privately-held precision oncology company Viracta Therapeutics. In an 8-K filing Tuesday, the company said each of the five proposals related to the merger was approved by the requisite vote at the special shareholder meeting held Feb. 22, paving way for the closing of the transaction. Sunesis shares were climbing 26.46% to … Full story available on Benzinga.com

NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Sunesis Pharmaceuticals, Inc. ("SNSS" or the "Company") (SNSS)…

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesis Pharmaceuticals, Inc. (NasdaqGS: SNSS) with Viracta Therapeutics, Inc. pursuant to which Sunesis shareholders will end up owning just 14% of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger u

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares shot up 11.9% during mid-day trading on Friday . The stock traded as high as $1.55 and last traded at $1.46. 1,999,292 shares were traded during trading, an increase of 177% from the average session volume of 721,360 shares. The stock had previously closed at $1.30. A number of analysts […]